×

BRIEF-Merck reports results of mid-stage study of experimental diabetes drug

Oct 3 (Reuters) - Merck :

* Phase iib data showed merck's investigational once-weekly dpp-4 inhibitor

mk-3102 significantly lowered blood sugar in patients with type 2 diabetes

* Mk-3102 significantly reduced hba1c compared to placebo from a mean baseline

of approximately 8 percent across all doses

((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))

((For more news, please click here ))